Dyskinesia News and Research

RSS
Neurocrine completes enrollment in Phase III clinical trial of NBI-98854 in tardive dyskinesia patients

Neurocrine completes enrollment in Phase III clinical trial of NBI-98854 in tardive dyskinesia patients

Pitt researchers figure out how to quantify beating action of cilia

Pitt researchers figure out how to quantify beating action of cilia

Severe dyskinesias rare in community Parkinson’s cohort

Severe dyskinesias rare in community Parkinson’s cohort

Pharma Two B reports positive results from P2B001 Phase IIb study for treatment of early stage PD

Pharma Two B reports positive results from P2B001 Phase IIb study for treatment of early stage PD

Clinical studies confirm safety, efficacy of opicapone in Parkinson’s disease patients

Clinical studies confirm safety, efficacy of opicapone in Parkinson’s disease patients

NTCELL Phase I/IIa clinical study meets primary endpoint in patients with Parkinson’s disease

NTCELL Phase I/IIa clinical study meets primary endpoint in patients with Parkinson’s disease

FVCG portfolio companies selected to present research at Bio International 2015

FVCG portfolio companies selected to present research at Bio International 2015

Neurocrine reports net loss of $1.2 million for first quarter 2015

Neurocrine reports net loss of $1.2 million for first quarter 2015

New treatment shows promise in easing symptoms of Parkinson's disease

New treatment shows promise in easing symptoms of Parkinson's disease

Neurocrine Biosciences, Mitsubishi Tanabe to develop and commercialize NBI-98854 in select Asian markets

Neurocrine Biosciences, Mitsubishi Tanabe to develop and commercialize NBI-98854 in select Asian markets

First randomized, controlled trial of pharmacotherapy in PCD patients now in place

First randomized, controlled trial of pharmacotherapy in PCD patients now in place

Enrollment completed in Pharma Two B's P2B001 Phase IIb study for Parkinson's disease treatment

Enrollment completed in Pharma Two B's P2B001 Phase IIb study for Parkinson's disease treatment

NeuroPerspective features comprehensive reviews of schizophrenia, spinal cord injury

NeuroPerspective features comprehensive reviews of schizophrenia, spinal cord injury

Study: Levodopa-carbidopa intestinal gel improves quality of life in advanced PD patients

Study: Levodopa-carbidopa intestinal gel improves quality of life in advanced PD patients

Researchers close to novel therapy to treat levodopa-induced dyskinesia

Researchers close to novel therapy to treat levodopa-induced dyskinesia

Young Researcher's Meeting on Primary Ciliary Dyskinesia to be held in Bern, Switzerland

Young Researcher's Meeting on Primary Ciliary Dyskinesia to be held in Bern, Switzerland

FDA approves RYTARY for Parkinson's disease treatment

FDA approves RYTARY for Parkinson's disease treatment

Brandeis University researchers capture highest resolution images of cilia ever

Brandeis University researchers capture highest resolution images of cilia ever

Neurocrine Biosciences' NBI-98854 drug gets breakthrough designation for tardive dyskinesia

Neurocrine Biosciences' NBI-98854 drug gets breakthrough designation for tardive dyskinesia

Levodopa dose linked to malnutrition risk in Parkinson’s disease

Levodopa dose linked to malnutrition risk in Parkinson’s disease